Skip to content
  • About
  • Board
  • News
  • Sign Up
  • Contact

Visit

vjoncology logo
VJHemOnc
Logo
  • Home (current)
  • Diseases
    CLL
    Multiple Myeloma
    Myeloproliferative Neoplasms
    ALL
    AML
    Lymphoma
    View all Diseases
  • Topics
    Transplantation
    Measurable Residual Disease
    CAR-T & Cellular Therapy
    Pharmacy
    Nursing
    Supportive Care
    View all Topics
  • Conferences
    ASH
    2019
    MPN Advances Day
    2019
    iwCAR-T
    2019
    COSTEM
    2019
    ESMO
    2019
    iwCLL
    2019
    View all Conferences
  • Features
  • Podcasts
    • About
    • Board
    • News
    • Sign Up
    • Contact

APR-246

3:03
Mutant p53 re-activator APR-246 in MDS/AML
David Sallman
1:22
MDS updates from ASH 2019
David Steensma
1:45
What’s to come for MDS therapy?
David Sallman
3:33
Targeting BCL-2 in older AML: novel venetoclax combinations
Andrew Wei
3:24
Data for APR-246 and azacitidine in patients with mTP53 MDS and AML
David Sallman
1:56
Promising approaches and clinical trials in MDS
David Steensma
1:06
Is there hope for treating TP53-mutated MDS?
Mark Levis
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Continue

Please enter your details if you would like to receive the latest hemonc news and updates

Sign up
Disease Channels
  • CLL
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • ALL
  • AML
  • Lymphoma
  • View all
Join our community

Keep up-to-date via social media

Sign up for email updates

Get great new content delivered to your inbox

Sign up
mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJHemOnc logo
The content of VJHemOnc is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy